PPT-Unpicking the Targets in Multiple Myeloma

Wednesday 13 th March 2013 T cells. What is smouldering myeloma? Smouldering myeloma (also known as asymptomatic myeloma) is a veryslow-growing type of myeloma. Myeloma, also known as multiple myeloma, is a type of bone marrow cancerari Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Round Cell Tumors. Wendy Blount, DVM. Round Cell Tumors. Lymphoma. Mast Cell Tumor. Plasma Cell Tumor. Extramedullary Plasmacytoma. Multiple myeloma . Histiocytic Disease. Transmissible Venereal Tumor. Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. Study of . clinocopathological. profile and chromosomal abnormalities by FISH in newly diagnosed multiple myeloma. Investigator – Dr. . Sukanya. S K.. Guide: Dr. . Shivani. . Vignesh. .. Co-guide- Dr . Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . 2 Foreword The reductions in antibiotic use that have been achieved by the UK livestock sectors over the last ve years has been a great success story, and the creation of the previous sector tar Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Maryam-kabootari. MD. Research Institute for Endocrine Sciences . Shahid. . Beheshti. University of Medical Sciences. mordad. 95. Diabetes . insipidus. (DI) belongs to the spectrum of . polyuric. Grace B. Athas, Ph.D. . MLS. Department of pathology, LSUHSC. CLPC Spring seminar series, 2018 . Learning objectives. Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT. [Hospital]. [date]. Myeloma: Symptoms to diagnosis . Can we do better?.